ARS Pharmaceuticals
SPRY
SPRY
184 hedge funds and large institutions have $960M invested in ARS Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 58 increasing their positions, 55 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
4.37% more ownership
Funds ownership: 73.37% → 77.73% (+4.4%)
5% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 55
41% less call options, than puts
Call options by funds: $2.67M | Put options by funds: $4.54M
Holders
184
Holding in Top 10
3
Calls
$2.67M
Puts
$4.54M
Top Buyers
| 1 | +$16.5M | |
| 2 | +$13.8M | |
| 3 | +$12.9M | |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$12.6M |
| 5 |
LCS
Levin Capital Strategies
New York
|
+$8.77M |
Top Sellers
| 1 | -$12.1M | |
| 2 | -$9.04M | |
| 3 | -$6.53M | |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$5.3M |
| 5 |
RA
Royce & Associates
New York
|
-$3.61M |